Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
Peter Martin(Northwestern University), John P. Leonard(New York University), Ari Melnick(Cornell University), Paul J. Christos(Cornell University), Jia Ruan(Cornell University), Amy Chadburn(Cornell University), Rubén Niesvizky(Cornell University), Rebecca Elstrom(Acentech (United States)), Morton Coleman(Cornell University), Scott Ely(NewYork–Presbyterian Hospital), Daniel M. Knowles(Cornell University), Selina Chen‐Kiang(NewYork–Presbyterian Hospital), Maurizio DiLiberto(NewYork–Presbyterian Hospital), Richard R. Furman(Cornell University)
Cited by 340
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k